Accuray (ARAY) Income from Non-Controlling Interests (2011 - 2025)
Accuray's (ARAY) quarterly Income from Non-Controlling Interests came in at $439000.0 in Q2 2025, up 709.72% year-on-year from $54216.1 in Q2 2024, and down 88.53% quarter-over-quarter from $3.8 million in Q4 2024.
Accuray (ARAY) Income from Non-Controlling Interests (2011 - 2025) Analysis & Trends
Accuray's Income from Non-Controlling Interests history runs 12 years deep, the most recent figure standing at $439000.0 for Q2 2025.
- On a quarterly basis, Income from Non-Controlling Interests rose 709.72% year-over-year to $439000.0 in Q2 2025; TTM through Jun 2025 was $5.8 million, a 504.17% increase from a year earlier, with the FY2025 full-year figure at $439000.0, up 709.72% from the prior year.
- Income from Non-Controlling Interests retreated to $439000.0 in Q2 2025 per ARAY's latest filing, from $3.8 million in the prior quarter.
- Across five years, Income from Non-Controlling Interests topped out at $3.8 million in Q4 2024 and bottomed at -$1.2 million in Q3 2021.
- The 5-year median for Income from Non-Controlling Interests is $431000.0 (2023), against an average of $505461.5.
- Across the five-year window, Income from Non-Controlling Interests plunged 1114.29% in 2021 and soared 709.72% in 2025, its largest moves.
- Year by year, Income from Non-Controlling Interests stood at $740000.0 in 2021, then surged by 162.97% to $1.9 million in 2022, then slumped by 47.17% to $1.0 million in 2023, then jumped by 272.47% to $3.8 million in 2024, then plunged by 88.53% to $439000.0 in 2025.
- Per Business Quant, the three latest ARAY Income from Non-Controlling Interests figures stand at $439000.0 (Q2 2025), $3.8 million (Q4 2024), and $1.6 million (Q3 2024).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Inc. Minority (Qtr) |
|---|---|---|---|---|---|
| 1 | Abbott Laboratories | 183.73 Bn | 176.43 Bn | 6.27 Bn | - |
| 2 | Stryker | 129.05 Bn | 126.17 Bn | 3.81 Bn | - |
| 3 | Medtronic | 108.52 Bn | 99.30 Bn | 6.41 Bn | 16.00 Mn |
| 4 | Boston Scientific | 68.63 Bn | 67.18 Bn | 3.61 Bn | -2.00 Mn |
| 5 | Edwards Lifesciences | 48.43 Bn | 44.76 Bn | 1.29 Bn | - |
| 6 | Dexcom | 28.36 Bn | 27.24 Bn | 750.30 Mn | - |
| 7 | GE HealthCare Technologies | 28.14 Bn | 25.85 Bn | 1.98 Bn | 22.00 Mn |
| 8 | Smith & Nephew | 26.89 Bn | 26.32 Bn | - | - |
| 9 | Koninklijke Philips | 24.25 Bn | 21.12 Bn | 2.07 Bn | -5.85 Mn |
| 10 | Accuray | 28,565.06 | -38.51 Mn | 25.29 Mn | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2025 | 439,000.00 |
| Dec 31, 2024 | 3.83 Mn |
| Sep 30, 2024 | 1.60 Mn |
| Jun 30, 2024 | -72,000.00 |
| Dec 31, 2023 | 1.03 Mn |
| Sep 30, 2023 | -427,000.00 |
| Jun 30, 2023 | 431,000.00 |
| Dec 31, 2022 | 1.95 Mn |
| Sep 30, 2022 | -1.07 Mn |
| Jun 30, 2022 | -368,000.00 |
| Dec 31, 2021 | 740,000.00 |
| Sep 30, 2021 | -1.17 Mn |
| Jun 30, 2021 | -340,000.00 |
| Dec 31, 2020 | 1.02 Mn |
| Sep 30, 2020 | 1.09 Mn |
| Jun 30, 2020 | -28,000.00 |
| Mar 31, 2020 | -149,000.00 |
| Mar 31, 2018 | 319,000.00 |
| Dec 31, 2017 | 102,000.00 |
| Sep 30, 2017 | 22,000.00 |